Normal and genetically engineered skeletal muscle cells (myoblasts) show promise as drug delivery vehicles and as therapeutic agents for treating muscle degeneration in congenital myopathies. Transplanted myoblasts may be used to correct defects in well characterized inherited myopathies such as Duchenne muscular dystrophy. In addition, myoblasts may provide genes to correct myopathies that are not understood at the molecular level. Finally, genetically engineered myoblasts can be used to deliver nonmuscle recombinant proteins to the circulation. Candidates for this type of delivery system include hormones, coagulation factors, growth factors and antitumor agents with broad applications ranging from the treatment of inherited hormone deficiencies to symptoms of aging, Parkinson's disease, heart disease and cancer. Myoblast transplantation poses unique challenges in comparison to organ transplants. In contrast to organs, transplanted myoblasts fuse and become incorporated into the multinucleated muscle fibers of the host. However, the immunobiology of myoblast transplantation is poorly understood. The use of myoblasts from a """"""""universal donor"""""""" would greatly increase the general utility of myoblast transplantation. However, allogeneic myoblasts are rapidly rejected unless immunosuppressants are administered. Continuous immunosuppression is associated with toxic side effects. Furthermore, chronic administration of immunosuppressive drugs may affect the clinical course of the muscle disease for which myoblast- mediated gene therapy is intended or affect the fusion of transplanted myoblasts. Alternate strategies of immunosuppression which are transient, but lead to the long term maintenance of allogeneic myoblasts are needed. We have shown that two different transient immunosuppressive treatments result in long term retention of allogeneic myoblasts in mice. The mechanism by which these transient treatments lead to persistent survival of allogeneic myoblasts is unknown. Several mechanisms have been proposed for transient immunosuppressive treatment to prolong allograft survival. These models have different implications for the fate of the original transplanted myoblasts after muscle injury, for the survival of subsequent myoblast transplants and for the formation of stem cells from the transplanted myoblasts. The goal of this research is to determine whether persistent survival of myoblasts with transient immunosuppressive treatment is due to the development of unresponsiveness in the host immune system or instead due to decrease in the expression of molecules involved in allograft rejection by the donor myoblasts. We will also determine if allograft rejection can be blocked by using myoblasts which are genetically defective in lCAM-1. Finally, we will determine if stem cells arise from the implanted cells during transient immunosuppressive treatment. These studies have direct applications to therapeutic approaches to inherited and acquired disease using myoblasts as vehicles for gene delivery.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AR043410-04
Application #
2769612
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1995-09-01
Project End
2000-08-31
Budget Start
1998-09-01
Budget End
2000-08-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Emory University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Luskin, Marla B (2008) Gene transfer to the rodent embryo by retroviral vectors. Methods Mol Biol 461:201-20
Friday, B B; Pavlath, G K (2001) A calcineurin- and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells. J Cell Sci 114:303-10
Horsley, V; Friday, B B; Matteson, S et al. (2001) Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway. J Cell Biol 153:329-38
Kegley, K M; Gephart, J; Warren, G L et al. (2001) Altered primary myogenesis in NFATC3(-/-) mice leads to decreased muscle size in the adult. Dev Biol 232:115-26
Abbott, K L; Robida, A M; Davis, M E et al. (2000) Differential regulation of vascular smooth muscle nuclear factor kappa-B by G alpha q-coupled and cytokine receptors. J Mol Cell Cardiol 32:391-403
Miller, K J; Thaloor, D; Matteson, S et al. (2000) Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle. Am J Physiol Cell Physiol 278:C174-81
Friday, B B; Horsley, V; Pavlath, G K (2000) Calcineurin activity is required for the initiation of skeletal muscle differentiation. J Cell Biol 149:657-66
Pavlath, G K; Luskin, M B (1999) Gene transfer to the rodent embryo by retroviral vectors. Methods Mol Biol 97:519-38
Abbott, K L; Friday, B B; Thaloor, D et al. (1998) Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. Mol Biol Cell 9:2905-16
Boss, V; Abbott, K L; Wang, X F et al. (1998) The cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) proteins are expressed in vascular smooth muscle cells. Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase C-coupled cell surface J Biol Chem 273:19664-71